Connecticut is currently home to 1225 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
NCT06292923
Recruiting
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomized, double-blind placebo-controlled, multicenter dose-ranging study is to evaluate the use of nasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS). The primary objectives that this study aims to answer are: 1. To determine the safety and tolerability of 50 μg/dose and 100 μg/dose of foralumab nasa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/16/2025
Locations: Yale, North Haven, Connecticut
Conditions: Secondary Progressive Multiple Sclerosis
Register for Updates
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
NCT06027554
Recruiting
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central... Read More
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
01/16/2025
Locations: UConn Health, Farmington, Connecticut
Conditions: Frailty, Mild Cognitive Impairment, Aging
Register for Updates
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
NCT06513819
Recruiting
The focus of this pilot will be on falls and neurocognitive symptoms, and the impact of alcohol, cannabis use, and medications on these outcomes. The rationale is that alcohol use at any level may interact with neurocognitively active medications, alcohol, and cannabis use leading to falls and impaired cognition.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
01/15/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Hiv, Alcohol Drinking, Fall, Cannabis Use
Register for Updates
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
NCT05820087
Recruiting
The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
01/15/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
Register for Updates
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
NCT05428969
Recruiting
This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Register for Updates
Open-label Study of BBO-8520 in Adult Subjects with KRASG12C Non-small Cell Lung Cancer
NCT06343402
Recruiting
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C, Metastatic Lung Cancer, Advanced Lung Carcinoma
Register for Updates
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035
Recruiting
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
Gender:
ALL
Ages:
Between 29 days and 21 years
Trial Updated:
01/14/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Acute Myeloid Leukemia
Register for Updates
FSL2 Post Approval Study for Pediatric and Young Adults Patients
NCT04959552
Recruiting
This is a prospective, multi-center, non-randomized, single-arm study intended to characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations.
Gender:
ALL
Ages:
Between 4 years and 30 years
Trial Updated:
01/14/2025
Locations: Yale Pediatric Endocrinology Clinic, New Haven, Connecticut
Conditions: Diabete Mellitus
Register for Updates
Von Willebrand Factor in Pregnancy (VIP) Study
NCT04146376
Recruiting
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding. This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum peri... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Von Willebrand Diseases
Register for Updates
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
NCT04217551
Recruiting
A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
Register for Updates
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/11/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)
NCT05776563
Recruiting
The goal of this clinical trial is to learn about the effects of high blood glucose levels in the brain and assess if the changes seen in individuals with poorly control T2DM can be reversed with good glucose control. The main question\[s\] it aims to answer are: * To determine, whether abnormalities in brain glucose transport seen in individuals with uncontrolled diabetes, can be improved with better glucose control. * Assess which factors, (duration of diabetes mellitus (DM) and glycemic con... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/10/2025
Locations: Yale New Haven Hospital (YNHH) Research Unit (HRU), New Haven, Connecticut
Conditions: Diabetes Mellitus, Type 2
Register for Updates